Clinical Trial

Registry Study to Determine the Effectiveness and Safety of Weight Loss With Enavogliflozin in Patients With Type 2 Diabetes Mellitus

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 2, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This observational study is designed to assess the effects of Envlo Tablet or Envlomet SR Tablet on weight loss and safety in patients with Type 2 diabetes, conducted in real primary care settings over a period of 24 weeks.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-05-21; most recent amendment 2025-08-28.
Status change: Recruiting → Active, Not Recruiting 2025-08-28
Status change: Not Yet Recruiting → Recruiting 2024-07-02
Trial Details
NCT Number NCT06427083
Lead Sponsor Daewoong Pharmaceutical Co. LTD.
Conditions Type 2 Diabetes Mellitus
Enrollment 200 participants
Start Date 2024-06-11
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-02